Tim Wentworth, the brand new CEO of Walgreens Boots Alliance, is changing the corporate’s prime healthcare companies govt as a part of a collection of broader management strikes.
John Driscoll, who joined Chicagoland-based Walgreens Boots in 2022 after the corporate purchased homecare enterprise CareCentrix, will step down from his position as president of U.S. healthcare April 1 and be succeeded by former Solera Well being CEO Mary Langowski. In a submitting with the U.S. Securities and Trade Fee, Walgreens stated that it expects Driscoll will keep on as a advisor “for a restricted time period.”
Langowski has been CEO of Solera Well being, a managed companies group that markets engagement-focused applied sciences to payers and employers, since 2020. Earlier than that, she was chief technique and company growth officer at CVS Well being from 2014 to 2016, work that helped set the stage for that firm’s buy of Aetna.
“I’ve had the prospect to collaborate with John Driscoll and the Walgreens staff for a number of years, and I’m getting into this new chapter excited concerning the alternatives forward,” Langwoski wrote in a put up on LinkedIn. “Healthcare wants extra of the belief, comfort and private connection People have with Walgreens. I’m trying ahead to working alongside Tim, this dynamic staff, and our rising community of payer, supplier, well being system and pharma companions to drive higher well being for sufferers. I’m additionally extremely appreciative of the continued help and partnership from John.”
Alongside Langowski’s hiring, Wentworth final week additionally introduced that interim CFO Manmohan Mahajan has taken on that position in a full-time capability and stated that Elizabeth Burger will be a part of his staff as chief human sources officer subsequent month after holding the identical position at manufacturing corporations FlowServe and HanesBrands.
Walgreens’ healthcare companies group rang up revenues of $1.9 billion within the firm’s most up-to-date fiscal quarter and posted an EBITDA lack of about $39 million. The corporate’s leaders are forecasting that the unit, which contains CareCentrix in addition to the Shields specialty pharmacy and a big funding within the VillageMD retail clinic chain, will break even this yr on an adjusted EBITDA foundation.
